Cargando…

Immunomodulatory Nanomedicine for the Treatment of Atherosclerosis

Atherosclerosis is the main underlying cause of cardiovascular diseases (CVDs), which remain the number one contributor to mortality worldwide. Although current therapies can slow down disease progression, no treatment is available that can fully cure or reverse atherosclerosis. Nanomedicine, which...

Descripción completa

Detalles Bibliográficos
Autores principales:	Peters, Linsey J. F., Jans, Alexander, Bartneck, Matthias, van der Vorst, Emiel P. C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8306310/ https://www.ncbi.nlm.nih.gov/pubmed/34300351 http://dx.doi.org/10.3390/jcm10143185

Ejemplares similares

G-Protein Coupled Receptor Targeting on Myeloid Cells in Atherosclerosis
por: van der Vorst, Emiel P. C., et al.
Publicado: (2019)

Chemokines and their receptors in Atherosclerosis
por: van der Vorst, Emiel P. C., et al.
Publicado: (2015)

Inflammatory Chemokines in Atherosclerosis
por: Gencer, Selin, et al.
Publicado: (2021)

Key Chemokine Pathways in Atherosclerosis and Their Therapeutic Potential
por: Márquez, Andrea Bonnin, et al.
Publicado: (2021)

MicroRNAs in Chronic Kidney Disease: Four Candidates for Clinical Application
por: Peters, Linsey J. F., et al.
Publicado: (2020)

ADAM10 and ADAM17, Major Regulators of Chronic Kidney Disease Induced Atherosclerosis?
por: Maas, Sanne L., et al.
Publicado: (2023)

Macrophage-targeted nanomedicine for the diagnosis and treatment of atherosclerosis
por: Chen, Wei, et al.
Publicado: (2021)

Biomimetic nanomedicines for precise atherosclerosis theranostics
por: Tao, Ying, et al.
Publicado: (2023)

Message in a Microbottle: Modulation of Vascular Inflammation and Atherosclerosis by Extracellular Vesicles
por: van der Vorst, Emiel P. C., et al.
Publicado: (2018)

Small Things Matter: Relevance of MicroRNAs in Cardiovascular Disease
por: Peters, Linsey J. F., et al.
Publicado: (2020)

Endothelial ACKR3 drives atherosclerosis by promoting immune cell adhesion to vascular endothelium
por: Gencer, Selin, et al.
Publicado: (2022)

Adipocyte calcium sensing receptor is not involved in visceral adipose tissue inflammation or atherosclerosis development in hyperlipidemic Apoe(−/−) mice
por: Sundararaman, Sai Sahana, et al.
Publicado: (2021)

Exploring the Role of Serotonin as an Immune Modulatory Component in Cardiovascular Diseases
por: Imamdin, Aqeela, et al.
Publicado: (2023)

Combating atherosclerosis with targeted nanomedicines: recent advances and future prospective
por: Nakhlband, Ailar, et al.
Publicado: (2018)

Editorial: Advances on targeted nanomedicines for atherosclerosis
por: Han, Qinggong, et al.
Publicado: (2022)

Calcium-Sensing Receptor (CaSR), Its Impact on Inflammation and the Consequences on Cardiovascular Health
por: Sundararaman, Sai Sahana, et al.
Publicado: (2021)

Adipocyte-Specific ACKR3 Regulates Lipid Levels in Adipose Tissue
por: Gencer, Selin, et al.
Publicado: (2021)

PCSK9 Imperceptibly Affects Chemokine Receptor Expression In Vitro and In Vivo
por: Sundararaman, Sai Sahana, et al.
Publicado: (2021)

Macrophage-targeted nanomedicine for the diagnosis and management of atherosclerosis
por: Hu, Ping Ping, et al.
Publicado: (2022)

Endothelial ADAM10 controls cellular response to oxLDL and its deficiency exacerbates atherosclerosis with intraplaque hemorrhage and neovascularization in mice
por: van der Vorst, Emiel P. C., et al.
Publicado: (2023)

Correction to: Transcriptome signature of miRNA-26b KO mouse model suggests novel targets
por: van der Vorst, Emiel P. C., et al.
Publicado: (2021)

Transcriptome signature of miRNA-26b KO mouse model suggests novel targets
por: van der Vorst, Emiel P. C., et al.
Publicado: (2021)

PCSK9: A Multi-Faceted Protein That Is Involved in Cardiovascular Biology
por: Sundararaman, Sai Sahana, et al.
Publicado: (2021)

High-Density Lipoprotein Modifications: A Pathological Consequence or Cause of Disease Progression?
por: Márquez, Andrea Bonnin, et al.
Publicado: (2020)

Anti-Inflammatory and Immunomodulatory Mechanism of Tanshinone IIA for Atherosclerosis
por: Chen, Zhuo, et al.
Publicado: (2014)

Theranostic nanomedicine for cancer detection and treatment
por: Fan, Zhen, et al.
Publicado: (2014)

Gouty Offense in Patients With Obstructive Coronary Artery Disease Despite State‐of‐the‐Art Therapy
por: Döring, Yvonne, et al.
Publicado: (2018)

Role of G-Protein-Coupled Receptors in Cardiovascular Diseases
por: Gencer, Selin, et al.
Publicado: (2023)

Advances in nanomedicine for the treatment of ankylosing spondylitis
por: Xi, Yanhai, et al.
Publicado: (2019)

Magnetic-Assisted Treatment of Liver Fibrosis
por: Levada, Kateryna, et al.
Publicado: (2019)

Stimulus-Responsive Nanomedicines for Disease Diagnosis and Treatment
por: Liu, Gengqi, et al.
Publicado: (2020)

Nanomedicines in the treatment of acromegaly: focus on pegvisomant
por: Roelfsema, Ferdinand, et al.
Publicado: (2006)

Nanomedicine and versatile therapies for cancer treatment
por: Shukla, Aparna, et al.
Publicado: (2022)

Polymeric nanomedicines for the treatment of hepatic diseases
por: Luo, Feixiang, et al.
Publicado: (2022)

Ferritin-based nanomedicine for disease treatment
por: Zhu, Yuanjun, et al.
Publicado: (2023)

Nanomedicine approaches for treatment of hematologic and oncologic malignancies
por: Nteli, Polyxeni, et al.
Publicado: (2022)

Hematopoietic miR155 Deficiency Enhances Atherosclerosis and Decreases Plaque Stability in Hyperlipidemic Mice
por: Donners, Marjo M. P. C., et al.
Publicado: (2012)

MIF and CXCL12 in Cardiovascular Diseases: Functional Differences and Similarities
por: van der Vorst, Emiel P. C., et al.
Publicado: (2015)

Bioresponsive Polymers for Nanomedicine—Expectations and Reality!
por: Quader, Sabina, et al.
Publicado: (2022)

Fucoidans in Nanomedicine
por: Chollet, Lucas, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_640nsi8el1vcc860eu64ttr423